AOD-9604 Dosage, Protocol, and Fat Loss Guide (Non-Hormonal hGH Fragment)
AOD-9604 Peptide
AOD-9604 is a synthetic 16-amino-acid fragment derived from the C-terminal region of human growth hormone. It was developed and studied primarily for obesity and fat-metabolism research. Preclinical studies reported effects on lipolysis, lipogenesis, and body-fat regulation, but larger human clinical studies did not establish AOD-9604 as an effective obesity treatment.
How AOD-9604 Works
Fat-Metabolism Research → Lipolysis + Lipogenesis Pathways → Body-Composition Research
AOD-9604 has been investigated for effects on fat metabolism without reproducing the full growth-promoting activity of human growth hormone. Preclinical research reported increased lipolysis and reduced lipogenesis in animal models. Its exact mechanism remains incompletely defined, and the available evidence does not establish a simple direct pathway from AOD-9604 administration to clinically meaningful fat loss in humans.
AOD-9604 is a growth-hormone-derived peptide fragment rather than full-length growth hormone.
Much of the lipolysis and fat-oxidation evidence comes from animal and laboratory research.
Human obesity trials evaluated AOD-9604, but overall weight-loss efficacy was not established.
Modern subcutaneous research-use protocols should be distinguished from the oral and intravenous routes used in published human development studies.
AOD-9604 Research-Use Protocol
Important Evidence Distinction:
The 300–500 mcg subcutaneous protocol below reflects dosing commonly discussed in research-use and peptide communities. It was not established by the published human AOD-9604 obesity trials, which used substantially different doses and primarily oral administration.
The 300–500 mcg subcutaneous protocol below reflects dosing commonly discussed in research-use and peptide communities. It was not established by the published human AOD-9604 obesity trials, which used substantially different doses and primarily oral administration.
5 mg Vial + 3.0 mL BAC Water → 1.667 mg/mL → 1 Unit ≈ 16.67 mcg
Example Research-Use Setup
Vial
5 mg
Water
3.0 mL bacteriostatic water
Concentration
1.667 mg/mL
Conversion
1 unit ≈ 16.67 mcg
Weeks 1–4
Starting Research-Use Range
Dose
300 mcg daily
Units
≈ 18 units
Volume
≈ 0.18 mL
Frequency
Once daily
Weeks 5–12
Higher Research-Use Range
Dose
500 mcg daily
Units
≈ 30 units
Volume
≈ 0.30 mL
Frequency
Once daily
Research-Use Schedule
Commonly Discussed Timing
Morning / fasted
Research-Use Route
Subcutaneous
Commonly Discussed Cycle
8–12 weeks
Extended Framework
Up to 12–16 weeks
Simple Approach:
The gradual 300 mcg → 500 mcg progression is a commonly discussed research-use framework. It provides a simple way to document dose, syringe volume, and response over time, but it should not be interpreted as a titration schedule established through controlled human clinical trials.
The gradual 300 mcg → 500 mcg progression is a commonly discussed research-use framework. It provides a simple way to document dose, syringe volume, and response over time, but it should not be interpreted as a titration schedule established through controlled human clinical trials.
What the Human Research Actually Shows
Published Clinical Context
AOD-9604 underwent human drug-development studies for obesity and weight reduction.
A 12-week randomized study involving approximately 300 adults evaluated oral doses ranging from 1 mg to 30 mg daily.
That study reported a non-linear dose-response, with the largest reported weight-loss signal occurring in the 1 mg group, but published information was limited.
A larger 24-week OPTIONS study enrolled 536 adults and evaluated 0.25 mg, 0.5 mg, and 1 mg oral AOD-9604 once daily alongside diet and exercise.
The larger study did not demonstrate a statistically significant weight-loss benefit compared with placebo, and development for obesity was discontinued.
Published human development studies do not establish the modern 300–500 mcg subcutaneous protocol shown elsewhere on this page.
Why this matters:
AOD-9604 has genuine human research history, but that does not mean every modern research-use protocol is clinically validated. The subcutaneous 300–500 mcg framework and the oral doses used during pharmaceutical development represent different bodies of information and should remain clearly separated.
AOD-9604 has genuine human research history, but that does not mean every modern research-use protocol is clinically validated. The subcutaneous 300–500 mcg framework and the oral doses used during pharmaceutical development represent different bodies of information and should remain clearly separated.
How to Use AOD-9604 (Research-Use Context)
Common Research-Use Framework
Frequency
Once daily
Commonly Discussed Timing
Morning / fasted
Cycle Length
8–12 weeks
Optional Extension
Up to 12–16 weeks
Research-Use Route
Subcutaneous
Timing Context
Morning or fasted administration is commonly discussed in research-use fat-loss protocols.
Human clinical trials have not established that fasted administration improves AOD-9604 efficacy.
No clinically established best time of day exists for subcutaneous AOD-9604.
Route Context
Subcutaneous administration is common in modern research-use discussions.
Published human obesity-development studies primarily evaluated oral AOD-9604, with some earlier intravenous research.
Human clinical evidence for repeated subcutaneous administration remains limited.
Areas of Research-Use Interest
Fat-metabolism and lipolysis research
Body-composition research
Weight-management research
Comparison with full growth-hormone metabolic signaling
Cycle Length & Time Between Cycles
8–12 Week Research-Use Cycle → 4 Week Break → Reassess
Commonly Discussed Research-Use Framework
Typical Cycle
8–12 weeks
Commonly Discussed Break
4 weeks
Extended Framework
12–16 weeks on, followed by 4–6 weeks off
Required Clinical Off-Period
Not established
Evidence distinction:
The 8–12 week cycle, 4-week break, and longer 12–16 week framework are commonly discussed in research-use settings. Human clinical trials have not established that these cycle lengths or washout periods are required for AOD-9604 effectiveness or safety.
The 8–12 week cycle, 4-week break, and longer 12–16 week framework are commonly discussed in research-use settings. Human clinical trials have not established that these cycle lengths or washout periods are required for AOD-9604 effectiveness or safety.
Ways the Research-Use Framework Is Structured
Option 1
8–12 weeks on, 4 weeks off
Commonly discussed as the standard-length research-use framework.
Option 2
12–16 weeks on, 4–6 weeks off
Represents the longer end of research-use discussions.
Option 3
Defined body-composition research period
Use is sometimes limited to a defined research phase rather than continuous exposure.
Why reassess?
There is no established evidence that AOD-9604 requires a metabolic “reset” or that continuous exposure causes a predictable loss of responsiveness. Break periods should therefore be described as research-use conventions rather than proven biological requirements.
There is no established evidence that AOD-9604 requires a metabolic “reset” or that continuous exposure causes a predictable loss of responsiveness. Break periods should therefore be described as research-use conventions rather than proven biological requirements.
Clinical vs Research-Use Dosing
Research-Use SC Framework → Separate From → Human Oral Clinical Development
Research-Use Context
300–500 mcg Daily
Commonly discussed SC research-use range
Clinical Validation
Not established for this SC range
Human Clinical Development
12-Week Study
Oral 1, 5, 10, 20, or 30 mg daily
24-Week OPTIONS Study
Oral 0.25, 0.5, or 1 mg daily
Outcome
Larger trial did not demonstrate significant weight-loss efficacy
Simple takeaway:
The clinical numbers and the modern research-use numbers should not be directly compared as though one is simply a higher or lower version of the other. Route, formulation, dose, and study purpose were different.
The clinical numbers and the modern research-use numbers should not be directly compared as though one is simply a higher or lower version of the other. Route, formulation, dose, and study purpose were different.
Reconstitution & Dose Conversion (5 mg Vial)
Example Reconstitution Setup
Vial
5 mg
Water
3.0 mL bacteriostatic water
Concentration
1.667 mg/mL
Conversion
1 unit ≈ 16.67 mcg
Conversion Reference
18 units ≈ 300 mcg / 0.18 mL
24 units ≈ 400 mcg / 0.24 mL
30 units ≈ 500 mcg / 0.30 mL
60 units ≈ 1 mg / 0.60 mL
Reconstitution Steps
Draw 3.0 mL bacteriostatic water using a sterile syringe
Add the water slowly down the inside wall of the vial
Gently swirl or roll rather than shaking vigorously
Allow the contents to dissolve completely
Refrigerate after reconstitution
Research Context:
These values are mathematical concentration and syringe conversions. They do not establish an appropriate or clinically validated subcutaneous AOD-9604 dose.
These values are mathematical concentration and syringe conversions. They do not establish an appropriate or clinically validated subcutaneous AOD-9604 dose.
Solubility & Reconstitution Notes
What Is Known
FDA-reviewed bulk-material information reports AOD-9604 free base as water-soluble up to approximately 2 mg/mL.
The 5 mg / 3.0 mL example on this page produces a concentration of approximately 1.67 mg/mL, which is below that reported bulk-material solubility limit.
AOD-9604 is sensitive to formulation, processing, and environmental conditions that can contribute to aggregation or degradation.
Cloudiness, visible particles, gel-like material, or unexpected precipitation should not automatically be considered normal or safe.
About acetic acid:
Acidified diluents are sometimes discussed in research and compounding contexts for peptides with solubility problems, but a universal “0.1 mL acetic acid + 2.9 mL BAC water” AOD-9604 preparation has not been established through human clinical studies. Formulation should be based on compound-specific manufacturer or pharmacy data rather than a generic online recipe.
Acidified diluents are sometimes discussed in research and compounding contexts for peptides with solubility problems, but a universal “0.1 mL acetic acid + 2.9 mL BAC water” AOD-9604 preparation has not been established through human clinical studies. Formulation should be based on compound-specific manufacturer or pharmacy data rather than a generic online recipe.
Acetic Acid in Research / Laboratory Use
Dilute acetic acid is sometimes used in laboratory peptide work to improve
solubility when a peptide does not dissolve adequately in water-based
solutions.
AOD-9604 has been specifically discussed in laboratory and research-use
settings as a compound that may benefit from acidified solvent conditions
when solubility or aggregation becomes a problem.
The purpose of acetic acid in this context is formulation and solubility,
not enhancement of AOD-9604's biological effect.
Published human AOD-9604 studies do not establish a standardized
acetic-acid reconstitution formula for subcutaneous administration.
Research Finding:
Laboratory peptide methods support the use of dilute acetic acid as a solubility aid for poorly soluble peptides, and AOD-9604 is included in research-use discussions of acidified reconstitution. However, a specific recipe such as 0.1 mL acetic acid plus 2.9 mL bacteriostatic water should be treated as a community or laboratory formulation approach rather than a clinically validated AOD-9604 preparation.
Laboratory peptide methods support the use of dilute acetic acid as a solubility aid for poorly soluble peptides, and AOD-9604 is included in research-use discussions of acidified reconstitution. However, a specific recipe such as 0.1 mL acetic acid plus 2.9 mL bacteriostatic water should be treated as a community or laboratory formulation approach rather than a clinically validated AOD-9604 preparation.
Visual Check
Clear, particle-free solution: Most reassuring visual appearance when the product is expected to form a clear solution.
Unexpected cloudiness or particles: May represent incomplete dissolution, aggregation, contamination, or formulation incompatibility.
Discoloration, visible debris, or major appearance change: Do not assume the preparation remains suitable based on appearance alone.
Storage & Stability
Unmixed Bulk Material
Storage data vary between AOD-9604 free base and AOD-9604 acetate.
FDA-reviewed manufacturer information for AOD-9604 free base reported stability for up to 3 years near −18°C, 1 year at approximately 0–7°C, and 6 months at 7–30°C when appropriately stored.
Manufacturer information for AOD-9604 acetate recommended 2–8°C for shorter-term storage and approximately −20°C for longer-term storage.
Peptide stability depends on formulation, moisture, temperature, impurities, and storage conditions.
After Reconstitution
Refrigeration at 2–8°C is commonly used for research-use preparations.
A 3–4 week use window is commonly discussed in research-use settings but is not a universally established stability period for every AOD-9604 formulation.
Follow formulation-specific stability information supplied by the manufacturer, pharmacy, or testing laboratory whenever available.
Supply Planning (Research-Use Framework)
What this table assumes:
The calculations below are based only on the example 300 mcg daily for Weeks 1–4 followed by 500 mcg daily thereafter. They are supply-math examples, not clinical dosing recommendations.
The calculations below are based only on the example 300 mcg daily for Weeks 1–4 followed by 500 mcg daily thereafter. They are supply-math examples, not clinical dosing recommendations.
Supply Planning
8 Weeks
≈ 5 × 5 mg vials
12 Weeks
≈ 8 × 5 mg vials
16 Weeks
≈ 11 × 5 mg vials
Daily Administrations
56–112 across 8–16 weeks
Monitoring During Use
Body weight and body-composition trends
Waist circumference when relevant to the research goal
Injection-site tolerance with subcutaneous research-use administration
Any new or unexpected systemic symptoms
Glucose-related or metabolic laboratory markers when clinically appropriate
IGF-1 context:
Human oral-development studies did not detect statistically significant differences in IGF-1 between AOD-9604 and placebo groups. That finding should not be interpreted as proof that no monitoring is ever appropriate, particularly because modern subcutaneous use has not been adequately characterized in humans.
Human oral-development studies did not detect statistically significant differences in IGF-1 between AOD-9604 and placebo groups. That finding should not be interpreted as proof that no monitoring is ever appropriate, particularly because modern subcutaneous use has not been adequately characterized in humans.
Benefits & Research Findings
Preclinical studies have reported increased lipolysis and reduced lipogenesis in animal models.
Animal research has reported effects on body weight, adipose tissue, and fat oxidation.
Early human obesity research reported a modest weight-loss signal at certain oral doses.
The larger 24-week human obesity study did not demonstrate significant weight-loss efficacy compared with placebo.
Human development studies did not demonstrate the same GH / IGF-1 profile expected from full-length growth hormone.
Evidence note:
AOD-9604's reputation as a fat-loss peptide is largely driven by preclinical metabolic findings and early clinical-development signals. The larger human obesity program ultimately did not establish sufficient efficacy for weight reduction.
AOD-9604's reputation as a fat-loss peptide is largely driven by preclinical metabolic findings and early clinical-development signals. The larger human obesity program ultimately did not establish sufficient efficacy for weight reduction.
Potential Side Effects & Safety Considerations
Human safety data exist primarily from oral and intravenous clinical-development studies rather than modern subcutaneous protocols.
FDA found insufficient information to characterize the safety of compounded subcutaneous AOD-9604.
Injectable peptide preparations may carry immunogenicity risks related to aggregation, impurities, formulation, and product quality.
Injection-site irritation may occur with subcutaneous research-use administration.
Long-term safety of repeated subcutaneous AOD-9604 use has not been established.
Stacking Considerations
AOD-9604 is sometimes discussed alongside GLP-1 therapies, GH-axis compounds, or metabolic-support compounds in research-use settings.
Controlled human research has not established specific AOD-9604 combination protocols for fat loss or body composition.
Combining AOD-9604 with Tesamorelin or other GH-axis compounds introduces additional pathways that should not be treated as proven synergy.
Evidence for GLP-1 medications, NAD+, Tesamorelin, or other individual compounds should not automatically be interpreted as evidence for an AOD-9604 stack.
Important Notes
AOD-9604 is a synthetic growth-hormone-derived peptide fragment developed for obesity and metabolic research.
Human clinical research exists, but the larger obesity-development program did not establish significant weight-loss efficacy.
The 300–500 mcg subcutaneous framework shown on this page is research-use information rather than a clinically validated dosing regimen.
Human oral or intravenous doses should not be directly converted into equivalent subcutaneous doses.
FDA's review found insufficient human information to assess safety and effectiveness of compounded subcutaneous AOD-9604.
Research-use cycle lengths, breaks, fasted timing, and combination protocols should be distinguished from established clinical requirements.
Bottom line:
AOD-9604 has both preclinical metabolic research and genuine human clinical-development history. The useful research-use information can remain on this page, but it should be kept clearly separate from what controlled human trials actually established.
AOD-9604 has both preclinical metabolic research and genuine human clinical-development history. The useful research-use information can remain on this page, but it should be kept clearly separate from what controlled human trials actually established.
Important Disclaimer
AOD-9604 is not FDA-approved. This content is for educational purposes only.
Research & References
Primary Research
- Wilding J. AOD-9604 Metabolic. Current Opinion in Investigational Drugs. 2004.
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. 2026.
Note: AOD-9604's later-stage human obesity trials (including the Phase III program often referred to as the OPTIONS study) were discontinued and, to our knowledge, were not published in a peer-reviewed journal indexed on PubMed. The dosing and enrollment details described above reflect publicly reported trial design rather than a peer-reviewed primary publication.
Comments
Post a Comment